The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
The anti-disialoganglioside (GD2) antibody dinutuximab (D) for second-line treatment (2LT) of patients (pts) with relapsed/refractory small cell lung cancer (RR SCLC): Results from part II of the open-label, randomized, phase II/III distinct study.
 
Martin Edelman
Stock and Other Ownership Interests - Biomarker Strategies; Neumedicines
Consulting or Advisory Role - ARMO BioSciences; BerGenBio; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; Syndax; WindMIL
Research Funding - Apexigen (Inst); Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); Nektar (Inst); United Therapeutics (Inst); Windmil (Inst)
Patents, Royalties, Other Intellectual Property - Patent application for radiopharmaceutical to treat small cell lung cancer. (Inst)
Travel, Accommodations, Expenses - ARMO BioSciences; BerGenBio; BerGenBio; Bristol-Myers Squibb
Other Relationship - AstraZeneca/MedImmune; Boehringer Ingelheim; Lilly; Takeda
 
Mikhail Dvorkin
No Relationships to Disclose
 
Konstantin K. Laktionov
No Relationships to Disclose
 
Alejandro Navarro
Consulting or Advisory Role - Boehringer Ingelheim; Bristol-Myers Squibb; Pfizer; Roche
Expert Testimony - Oryzon Genomics
Travel, Accommodations, Expenses - Boehringer Ingelheim; Pfizer
 
Oscar Juan-Vidal
Consulting or Advisory Role - AstraZeneca/MedImmune; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; Merck Sharp & Dohme; Pfizer; Roche/Genentech; Takeda
Research Funding - AstraZeneca Spain (Inst)
Travel, Accommodations, Expenses - Boehringer Ingelheim; Bristol-Myers Squibb; Merck Sharp & Dohme; Roche/Genentech
 
Vadim Kozlov
No Relationships to Disclose
 
Gil Golden
Employment - United Therapeutics
Leadership - United Therapeutics
Stock and Other Ownership Interests - United Therapeutics
Research Funding - United Therapeutics
Travel, Accommodations, Expenses - United Therapeutics
 
Odette Jordan
Employment - United Therapeutics
Stock and Other Ownership Interests - United Therapeutics
Research Funding - United Therapeutics
 
CQ Deng
Employment - United Therapeutics
Stock and Other Ownership Interests - United Therapeutics